Lixte Biotechnology Holdings Inc. LIXT stock price is finally showing some life as it reverses trend. LIXT is up 33% in the last 5 days and I will be evaluating many factors to determine just how hot the stock is.
The official heat level for LIXT is, a 🔥🔥🔥 3 out of 5.
Continue reading to see why I think it is just a 3 out of 5. There is some shocking takeaways from this article that you must read if you are interested in LIXT.
If you are interested in finding out more about me, famed stock picker, Alexander Goldman or if you’re interested in my HOT grading system, sign up today, it’s FREE!
👇 Sign up for our newsletter to get the latest 🔥🔥🔥🔥🔥 HOT stocks and trending stocks!👇 In fact, I will send you personally a 🔥🔥🔥🔥 HOT stock as a thank you for joining our FREE newsletter.
[thrive_leads id=’14274′]
Before I go over this exciting trending stock, I wanted to introduce myself. Hello 🙋♂️ My name is Alexander Goldman. I have been trading, at a very high level, breakout stocks and trending stocks for 20 years now. I’m accredited for establishing the coveted HOT grading system for trending stocks.
I found my home at Small Cap exclusive 4 years ago. Now, I’m helping traders find breakout stocks. Not to sound egotistical but I’m very good at finding small cap stocks that are winners.
What do I mean by big winners?
Stocks that move more than 100% in a month! LIXT Stock Price could?
Does that always happen, NO! But, I’m very consistent! Take a look at this article I wrote below, where I called 5 stocks, 3 losers and 2 winners and they all did what I thought!
The article is HERE and I shine a spotlight on these breakout stocks and also those losers!
Now, let’s go over some of the basic information on this stock before we get in the technical analysis and how I came up with HOT grade.
Lixte Biotechnology Holdings Company Information
Company Name: Lixte Biotechnology Holdings
Ticker: LIXT
Exchange: NASDAQ
Website: https://lixte.com/
Breakout Stock Lixte Biotechnology Holdings Company Summary:
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company, that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The firm focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development.
It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher’s disease, as well as cancer and neurodegenerative diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.
LIXT stock price is due to News?
January 12, 2022
Has led to an initial joint patent application covering LB-100 combination therapy with one of several other investigational compounds. The Company, NKI and Oncode Institute believe that the combination therapy would provide unexpectedly strong synergistic anti-cancer effects in cancer patients. The Company previously announced its entry into a collaboration with the NKI and the Oncode Institute to identify the most promising drugs to be used in combination with the Company’s LB-100 or with one of the Company’s LB-100 analogues to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.
Trending Stock LIXT 5 Day Chart
LIXT Stock Price HOT Stock Grade:
The official heat level for SMCE is, a 🔥🔥🔥3 out of 5 . Continue reading to see why I think it is just a 3 out of 5. Here are my takeaways on LIXT and why it is just a 3 out of 5.
The volume, which is basically demand of a stock is incredible due to the news lately. They filed a 10K today
The news, the 10K had plenty of positive news
The chart, it is consolidating and that is why it is not a 4 out of 5
The fundamentals, are strong but lack the profit margins I normally would like to see. Hence not a 5 out of 5
Marketing efforts, I have found marketing efforts around the investor awareness of this company which saved it from a 2 out of 5 rating.
To receive my 🔥🔥🔥🔥🔥 HOT stock as a thank you for joining our FREE newsletter, sign up today.
👇 Sign up for our newsletter to get the latest 🔥🔥🔥🔥🔥 HOT stocks and trending stocks!👇
[thrive_leads id=’14274′]
